Jun 10, 2020
Gastroparesis Market Analysis for the 7MM - Epidemiology and Forecasts to 2028
May 06, 2020
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results
Apr 08, 2020
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
Apr 02, 2020
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
Feb 25, 2020
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
Feb 25, 2020
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Nov 06, 2019
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results
May 22, 2019
Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
May 01, 2019
Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results
Feb 13, 2019
Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
Feb 05, 2019
Vanda Pharmaceuticals Takes a Stand Against Unnecessary Animal Research
Dec 03, 2018
Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis
Sep 13, 2018
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Apr 09, 2018
Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
Jan 07, 2018
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance
Oct 02, 2017
Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
Sep 13, 2017
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis